600 related articles for article (PubMed ID: 9814448)
1. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
2. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
[TBL] [Abstract][Full Text] [Related]
3. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
5. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
[TBL] [Abstract][Full Text] [Related]
6. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
8. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
9. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
[TBL] [Abstract][Full Text] [Related]
10. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
11. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
[TBL] [Abstract][Full Text] [Related]
12. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
13. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
Kung AW; Michon J; Tai KS; Chan FL
Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
15. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
Kahaly G; Diaz M; Just M; Beyer J; Lieb W
Thyroid; 1995 Apr; 5(2):107-11. PubMed ID: 7647569
[TBL] [Abstract][Full Text] [Related]
16. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
17. [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
Ardjomand N; Esche G; Fellner P; Lindner S; Panzitt M; Aigner R; Langmann A
Ophthalmologe; 2003 Dec; 100(12):1049-53. PubMed ID: 14704818
[TBL] [Abstract][Full Text] [Related]
18. [[111In]-DTPA-D-phenylalanine octreotide SPECT for the scintigraphic imaging of enhanced somatostatin-receptor density in endocrine ophthalmopathy].
Cordes M; Hosten N; Gräf KJ; Wenzel KW; Venz S; Keske U; Eichstädt H; Felix R
Rofo; 1994 Jan; 160(1):11-5. PubMed ID: 8305685
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
20. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
